4//SEC Filing
Hayashida Jon K. 4
Accession 0001209191-21-032101
CIK 0000718937other
Filed
May 11, 8:00 PM ET
Accepted
May 12, 5:05 PM ET
Size
23.0 KB
Accession
0001209191-21-032101
Insider Transaction Report
Form 4
Hayashida Jon K.
VP, Global Clinical, Medical
Transactions
- Sale
Common Stock
2021-05-10$125.22/sh−1,349$168,922→ 8,342 total - Exercise/Conversion
Common Stock
2021-05-10$29.80/sh+2,534$75,513→ 18,076 total - Exercise/Conversion
Common Stock
2021-05-10$35.98/sh+3,462$124,563→ 21,538 total - Exercise/Conversion
Common Stock
2021-05-10$27.53/sh+5,523$152,048→ 27,061 total - Exercise/Conversion
Common Stock Options
2021-05-10−2,534→ 750 totalExercise: $29.80From: 2019-06-14Exp: 2028-06-13→ Common Stock (2,534 underlying) - Exercise/Conversion
Common Stock Options
2021-05-10−5,523→ 9,774 totalExercise: $27.53From: 2021-03-20Exp: 2030-03-19→ Common Stock (5,523 underlying) - Exercise/Conversion
Common Stock
2021-05-10$16.15/sh+7,200$116,280→ 15,542 total - Exercise/Conversion
Common Stock Options
2021-05-10−7,200→ 0 totalExercise: $16.15From: 2019-03-15Exp: 2028-03-14→ Common Stock (7,200 underlying) - Exercise/Conversion
Common Stock Options
2021-05-10−3,462→ 8,564 totalExercise: $35.98From: 2020-03-14Exp: 2029-03-13→ Common Stock (3,462 underlying) - Sale
Common Stock
2021-05-10$124.13/sh−10,760$1,335,639→ 16,301 total
Footnotes (6)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.02 to $135.64, inclusive.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.85 to $135.64, inclusive.
- [F3]The options granted become exercisable as follows: 1/3 on 3/15/2019 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 3/15/2028.
- [F4]The options granted become exercisable as follows: 1/3 on 6/14/2019 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 6/14/2028.
- [F5]The options granted become exercisable as follows: 1/3 on 3/14/2020 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 3/14/2022.
- [F6]The options granted become exercisable as follows: 1/3 on 3/20/2021 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 3/20/2023.
Documents
Issuer
STAAR SURGICAL CO
CIK 0000718937
Entity typeother
Related Parties
1- filerCIK 0001781825
Filing Metadata
- Form type
- 4
- Filed
- May 11, 8:00 PM ET
- Accepted
- May 12, 5:05 PM ET
- Size
- 23.0 KB